Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MEDI (durvalumab), tremelimumab and radiation
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with either therapy
Pregnant women are excluded; breastfeeding should be discontinued if the mother is treated with cediranib and olaparib
Pregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN (TAK-)
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab; (Note: pregnancy testing should be performed within  days prior to randomization according to institutional standards for women of childbearing potential)
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with olaparib and atezolizumab
Pregnant women and women who are lactating; breastfeeding should be discontinued if the mother is treated with taselisib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with tremelimumab and MEDI
Pregnant women are excluded from this study; breastfeeding must be discontinued if the mother is treated with ruxolitinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with afatinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lenalidomide or pomalidomide
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with radiation
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ficlatuzumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with PT
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with bavituximab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with palbociclib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab
Pregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ramucirumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with selumetinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated nivolumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with PLX and sirolimus
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ponatinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AT and paclitaxel
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with talazoparib (BMN )
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with everolimus
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with natalizumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with the study drugs
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with WDVAX
Persons who are pregnant are excluded from this study; breastfeeding should be discontinued if the mother is treated with radiotherapy
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ipilimumab or nivolumab; a negative serum pregnancy test is required prior to study entry
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with BVD
Males and females of reproductive potential who are not using an effective method of birth control and females who are pregnant or breastfeeding or have a positive (urine or serum) pregnancy test prior to study entry\r\n* Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with these agents
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab, gemcitabine, and oxaliplatin
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with abemaciclib; a negative serum pregnancy test is required for women of childbearing potential prior to study entry
Breastfeeding should be discontinued
ENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: Pregnant women are excluded from this study; breastfeeding must be discontinued if the mother is treated
EXPANDED ACCESS COHORT: Pregnant women are excluded from this study; breastfeeding must be discontinued if the mother is treated
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with merestinib and LY
Active pregnancy or breast-feeding; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with gefitinib or osimertinib agents
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this protocol
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with dasatinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with VX-
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with M (VX-) and/or gemcitabine
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AT (onalespib)
Pregnant or breastfeeding women; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with pembrolizumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with gemcitabine or IMGN
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IMA-poly-ICLC vaccine
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with merestinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with chemoembolic agent
Breastfeeding should be discontinued if the mother wishes to participate in this study
Pregnant or lactating women are excluded from this study; breastfeeding should be discontinued if the mother is treated with radiation therapy
Pregnancy or breastfeeding (pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with oral THU-Dec
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with GBM-AD-poly vaccine
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lenalidomide
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with radiation
Pregnant or nursing patients will be excluded from the study; breastfeeding should be discontinued if the mother is treated with sunitinib or everolimus
Patients who are pregnant or breast feeding; breastfeeding should be discontinued if the mother is treated with selinexor
Pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with carfilzomib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with radiopharmaceutical agents
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated
Pregnant or lactating females; breastfeeding should be discontinued if the mother is treated with carfilzomib/lenalidomide
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with Combotox
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with pyrimethamine
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with rucaparib and mirvetuximab soravtansine
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with LMB- + SEL-
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with M
COHORT : HORMONE RECEPTOR POSITIVE BREAST CANCER: Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ONC
COHORT : TRIPLE NEGATIVE BREAST CANCER: Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ONC
COHORT : ENDOMETRIAL CANCER: Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ONC
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lenalidomide
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with clofarabine
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with these agents
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD and navitoclax
Pregnant and/or breastfeeding women or unable to maintain use of contraception while on study and for  days after the last dose of study drug; breastfeeding should be discontinued if the mother is treated with ONC
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with EGF and gefitinib
Pregnant or lactating women are excluded from this study; breastfeeding should be discontinued if the mother is treated with radiation therapy
Breastfeeding should be discontinued if the mother is treated with nivolumab
Breastfeeding must be discontinued if the mother is treated with pembrolizumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with fostamatinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with DAC-THU
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with trametinib
Breastfeeding should be discontinued if the mother wishes to participate in this study
Pregnant women, or women who intend to become pregnant during the study, are excluded from this study; breastfeeding should be discontinued if the mother is treated on study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IORT
Female patients who are breastfeeding; breastfeeding should be discontinued if the mother is treated with Pexa-Vec
Pregnant or lactating women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinib
Breastfeeding should be discontinued if the mother is treated with E TCR
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with SGI-
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with either dabrafenib, trametinib, or the combination of dabrafenib and trametinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lamivudine
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with anetumab ravtansine or MK- (pembrolizumab)
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with selumetinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is enrolled in the trial
Pregnant women are excluded; breastfeeding should be discontinued if the mother is treated on this study
Female participants pregnant or breast-feeding; breastfeeding should be discontinued if the mother is treated with the study drugs
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with CDX- (varlilumab) or nivolumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with SBRT
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with XL and nivolumab
Pregnancy and breastfeeding: pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with TRC
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cediranib and olaparib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with hydroxychloroquine
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with everolimus and fosbretabulin
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IL-
Pregnant women are excluded; breastfeeding should be discontinued if the mother is treated with cisplatin or radiation on this trial
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab
Pregnant or lactating females; breastfeeding should be discontinued if the mother is treated with isatuximab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with intraperitoneal interferons
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ruxolitinib
Pregnant and/or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab, dabrafenib, and trametinib
Pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lenalidomide
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with palbociclib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with durvalumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this protocol
Pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with oral THU-Dec
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with LMB-
Pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cesium 
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated lenvatinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with these agents
PHASE I AND II SCLC AND UROTHELIAL CARCINOMA EXPANSION COHORT: Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with CRLX and/or olaparib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IRX
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with dasatinib and not resumed until at least  weeks after the final dose
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with this agent
Pregnant women are excluded; breastfeeding should be discontinued if the mother is treated with mebendazole
Subject is pregnant or nursing; breastfeeding should be discontinued if the mother is treated with ACY-
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab
Pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with pembrolizumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with methoxyamine
Pregnant or nursing females are to be excluded; breastfeeding should be discontinued if the mother is treated with taladegib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with veliparib; this may also apply to other agents used in this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MEDI-
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with chemotherapy and/or radiation
Pregnant women and women who are lactating; breastfeeding should be discontinued if the mother is treated with -chloro-adenosine
Pregnant women and women who are lactating; breastfeeding should be discontinued if the mother is enrolled on this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with these agents
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cediranib or olaparib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IPdR
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with temozolomide
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with indium In  (In-) and Y-basiliximab-DOTA
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with GDC-
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN (TAK-) and ziv-aflibercept
Pregnant women are excluded from this study; breastfeeding should be discontinued prior to the mother being treated with the study drugs
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated
Must not be pregnant or breastfeeding; breastfeeding should be discontinued if the mother is treated azacitidine
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IPdR
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ipilimumab
Pregnant or lactating women are excluded from this study; breastfeeding should be discontinued if the mother is treated with radiation therapy
A nursing mother unwilling to discontinue breastfeeding; breastfeeding should be discontinued if the mother is treated with durvalumab, tremelimumab and radiation
Pregnant women are excluded from this study. Breastfeeding should be discontinued if the mother is treated with cenersen
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with CPI-
Pregnant or planning pregnancy within the next  months, or breastfeeding; breastfeeding should be discontinued if the mother is treated with -fluorouracil
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lenvatinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab
Pregnant women or women who expect to conceive a child are excluded from the study; breastfeeding should be discontinued if the mother is treated on this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AMG  through  week after receiving the last dose of study drug
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with high dose nelfinavir
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is enrolled
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with olaparib or AT
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with XL
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with BAL
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with Mylotarg
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with navitoclax and vistusertib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with olaparib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with olaparib or cediranib
Pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother participates in this trial
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with any of these agents
Pregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ibrutinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cediranib or olaparib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab
Pregnant women are excluded; breastfeeding should be discontinued if the mother is treated with sirolimus
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is enrolled
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ruxolitinib
Pregnant women are excluded from ECP; breastfeeding should be discontinued if the mother is treated with methoxsalen; pregnancy will be evaluated prior to the initiation of ECP
Pregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ibrutinib
Breastfeeding should be discontinued if the mother is treated with indenoisoquinolines
Pregnancy or nursing or unwilling to take adequate birth control during therapy \r\n* NOTE: Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with CDX- or CDX- and poly-ICLC
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ALT-
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with TRC
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with -FU/capecitabine; pregnancy testing will be completed on all female participants of child-bearing potential by urine analysis
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with TPI 
Pregnant or nursing women; breastfeeding should be discontinued if the mother is treated with MLN
Patient is pregnant or breast feeding; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is participating in this study
Pregnancy, nursing, or unwilling to take adequate birth control during therapy\r\n* NOTE: pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with INCB and MELITAC .
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with dabrafenib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN and/or romidepsin
Breastfeeding should be discontinued if the mother is treated with PF-
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with vorinostat
Pregnant women are excluded from this study, breastfeeding should be discontinued if the mother is treated with erlotinib or dasatinib
Pregnant/nursing women are excluded from this study; breastfeeding should be discontinued if the mother is treated with oxaliplatin or mitomycin C
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lenalidomide
Breastfeeding should be discontinued
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with afatinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with VX-
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with M (VX-)
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD and necitumumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ABT-
Pregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ibrutinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with proton radiotherapy
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with hydroxychloroquine
Pregnant or lactating women are excluded; breastfeeding should be discontinued if the mother is treated
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AMG 
Pregnant and nursing women; breastfeeding should be discontinued if the mother is treated with combination ETBX-, ETBX-, ETBX-
Pregnant women are excluded from this study; breastfeeding should be discontinued while the mother is receiving protocol therapy
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab and/or bevacizumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this research protocol
Pregnant or lactating females; breastfeeding should be discontinued if the mother is treated with pembrolizumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with pIL- EP + pembrolizumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cediranib and olaparib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with eribulin and gemcitabine
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IPI-
Pregnant or lactating women; women of childbearing potential must have a negative pregnancy test at screening; breastfeeding should be discontinued if the mother is treated on this study with idelalisib and ofatumumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with these agents and/or radiation
Subjects who are pregnant or breast-feeding; breastfeeding should be discontinued if the mother is treated with curcumin
Pregnant or breastfeeding women are excluded from this study; breastfeeding must be discontinued if the mother is treated with sunitinib
PHASE II: Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with pomalidomide
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated
Pregnant women are excluded from this study, breastfeeding should be discontinued if the mother is treated with trametinib monotherapy or trametinib in combination with GSK
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with GSK and GSK
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this protocol
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with neratinib and/or fulvestrant
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with dabrafenib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with either agent, and for  days after discontinuation of therapy
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with sunitinib
Breast-feeding should be discontinued if a nursing mother is to be treated on clinical trial
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ruxolitinib
Pregnant women are excluded; breastfeeding should be discontinued if the mother is treated with mebendazole
Pregnant women are excluded; breastfeeding should be discontinued prior to participation of the mother on study
Pregnant women are excluded from this study; breastfeeding must be discontinued while the mother is taking study drug and for at least  days after discontinuation of study drug
Pregnant women are excluded from this study; breastfeeding must be discontinued if the mother is treated with AMG 
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with CRLX
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with sunitinib
Pregnant women are excluded from this study, breastfeeding should be discontinued if the mother is treated with vorinostat
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated sorafenib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on either arm of the trial
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with neratinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on protocol
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on protocol
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with sonidegib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this clinical trial
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with bevacizumab
Pregnant women are excluded; breastfeeding should be discontinued if the mother is treated with eltrombopag
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab and eribulin
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cediranib or olaparib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with entinostat
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with E
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with these agents
Lactating or pregnant; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ibrutinib
Pregnant women and women who are lactating; breastfeeding should be discontinued if the mother is enrolled on this study
Pregnant or nursing; women of childbearing potential must have a negative serum pregnancy test performed within  days prior to the start of study therapy\r\n* Note: Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD/belinostat
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MK-
Pregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ibrutinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with paclitaxel
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated on this protocol
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated in this protocol
Breastfeeding should be discontinued if the mother is treated with sEphB-HSA
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MPDLA
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with terameprocol
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with erlotinib and onalespib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with belinostat
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MK- and/or dinaciclib
Pregnancy or breastfeeding (pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with oral tetrahydrouridine- decitabine [THU-Dec])
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with gemcitabine
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ibrutinib R-ICE
Pregnancy or lactation; breastfeeding should be discontinued if the mother is treated with this regimen
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MK-
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ipilimumab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with pioglitazone
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with dasatinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD (MK-)
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinib
Pregnant women are excluded; breastfeeding should be discontinued if the mother is treated on this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with erlotinib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN
Pregnant women are excluded; breastfeeding should be discontinued if the mother is treated with DMS
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with capecitabine or temozolomide or veliparib
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with BMN  or AT
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ivabradine
Female subjects who are pregnant, have a positive serum human chorionic gonadotrophin (hCG), or are lactating and intend to breast feed a child; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with NEPA
Pregnant or breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother participates in this trial
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with this agent
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with these agents
Pregnant women and women who are lactating; breastfeeding should be discontinued if the mother is enrolled on this study
Pregnant women and women who are lactating; breastfeeding should be discontinued if the mother is enrolled on this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with NT-I
Pregnant women and women who are lactating; breastfeeding should be discontinued if the mother is enrolled on this study
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with brentuximab
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with naltrexone
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with brentuximab vedotin
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with brentuximab vedotin
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ruxolitinib
Patients who are pregnant or nursing are excluded; breastfeeding should be discontinued if the mother is treated with cytotoxic chemotherapy
Pregnant or nursing women; breastfeeding should be discontinued if the mother is treated with INO-
Women who are pregnant or breastfeeding; breastfeeding should be discontinued if the mother is treated\r\nwith simvastatin
Pregnant or breast feeding; breastfeeding should be discontinued if the mother is treated with the vaccine
Women who are pregnant or breastfeeding; breastfeeding should be discontinued if the mother is treated with simvastatin
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with this vaccine
Women who are pregnant or breastfeeding; breastfeeding should be discontinued if the mother is treated with aspirin
Pregnant or breast feeding; Note: Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with Meriva
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with aspirin
Women must not be pregnant or breastfeeding; breastfeeding should be discontinued if the mother is treated with iloprost
Women who are pregnant or breastfeeding; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with pravastatin
Pregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with denosumab; there is no minimum amount of time since pregnancy/breastfeeding required before enrolling into the study; however, the date of delivery, pregnancy termination, or weaning from breastfeeding will be documented on case report forms; female subjects of child bearing potential and not willing to use, in combination with her partner, highly effective contraception during treatment will be excluded
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with this study agent
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with berberine; women are considered to be of child-bearing potential if they are not surgically sterile or under the age  and have menstruated within the last two years
Pregnant, breast-feeding, or women of childbearing potential unwilling to use a reliable contraceptive method; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with naproxen
Participants who are pregnant or breast feeding; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with Polyphenon E
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with aspirin
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with this agent
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with this drug
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ABT- and SCH
Breastfeeding must be discontinued for the duration of study participation and for one month after the last dose of the study agent if the mother is treated with cUAB
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with radiopharmaceutical agents
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with radiotherapy
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with Cu-MA
Women who are pregnant or may become pregnant, as well as those women who are breastfeeding, will be excluded from this study; breastfeeding should be discontinued if the mother is treated
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with SL- and azacitidine
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with APR-
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD
Pregnant or lactating women; breastfeeding should be discontinued if the mother receives F-FdCyd
Pregnant or lactating women: pregnant women are excluded from this study; breastfeeding should be discontinued for at least one day if the mother receives Ga-DOTATATE
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with LB
Pregnant women are excluded. Breastfeeding should be discontinued if the mother is treated with LUM.
